ClinicalTrials.gg
CompletedNCT00932022Updated Jan 21, 2013Results posted

Trospium Chloride XR in Obese Female Patients With Overactive Bladder

A Phase 4 interventional study of Trospium Chloride, Extended Release (XR) and placebo in Obesity, Overactive Bladder and Incontinence, sponsored by Allergan. Completed at 1 site in United States. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-01-21.

Sponsored by Allergan (part of AbbVie) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
127
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Study summary

This study evaluated the effectiveness of trospium chloride extended release (XR) in obese female patients with overactive bladder (OAB). Patients received either placebo and trospium chloride XR or placebo only. The study assessed the change from baseline in urinary frequency, urgency, and incontinence for trospium chloride XR versus a placebo-pill. The study was 14 weeks in duration.

02

Conditions studied

  • Obesity
  • Overactive Bladder
  • Incontinence
03

In context

Obesity

11,547 studies on the registry are indexed under Obesity; 2,050 are open to participants now.

This study's enrollment of 127 is above the median of 67 across 9,027 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.

Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.

First submitted before Allergan became part of AbbVie.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • OAB syndrome with Urgency, Urinary frequency and Urgency urinary incontinence
  • Non-smoker (refrained from any tobacco usage, including smokeless tobacco, nicotine patches, etc., for 6 months prior to the screening visit).
  • Obese

Exclusion criteria

Exclusion Criteria:

  • Chronic kidney failure
  • Abdominal bypass surgery for obesity
  • Moderate or severe memory impairment
  • Uncontrolled narrow angle glaucoma
  • Uncontrolled systemic disease
  • Concurrent dementia drugs: Aricept (donepezil), Namenda (memantine), Cognex (tacrine), Exelon (rivastigmine), Razadyne (galantamine), or similar drugs for dementia
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
127 participants (actual)

Study arms

  • Experimental
    trospium chloride XR 60 mg

    Placebo capsule taken orally once daily for 2 weeks followed by trospium chloride extended release (XR) 60 mg capsule taken orally once daily for 12 weeks.

    Drug: Trospium Chloride, Extended Release (XR) · Other: placebo

  • Placebo comparator
    placebo

    Placebo capsule taken orally once daily for 14 weeks.

    Other: placebo

Interventions

  • Trospium chloride extended release 60 mg capsule taken orally once daily for 12 weeks.

    Also known as: Sanctura XR™ 60 mg

  • Otherplacebo

    Placebo capsule taken orally once daily for either 2 weeks or 14 weeks.

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Urinary Urgency Incontinence (UUI)

    Patients recorded information about UUI (accidental leakage, urgency associated with void and urgency severity) in a 3-day diary at Baseline (Week 2) and Week 14. The daily average episodes of UUI was the sum of all UUI episodes over valid diary days during the 3-day diary period divided by the valid number of diary days with at least one valid bladder entry. The percent change from baseline was calculated as (Mean UUI at Week 14- Mean UUI at Week 2)/ Mean UUI at Week 2 X 100. A negative number percent change from baseline indicated an improvement.

    Time frame: Baseline (Week 2), Week 14

Secondary outcomes

  1. Percent Change From Baseline in Urgency Severity Associated With Toilet Voids

    Due to lack of evaluable data, analysis for this outcome measure was not performed.

    Time frame: Baseline (Week 2), Week 14

  2. Percent Change From Baseline in Voided Volume

    Due to lack of evaluable data, analysis for this outcome measure was not performed.

    Time frame: Baseline (Week 2), Week 14

  3. Percent Change From Baseline in Over Active Bladder (OAB)-Symptom Composite Score

    Due to lack of evaluable data, analysis for this outcome measure was not performed.

    Time frame: Baseline (Week 2), Week 14

  4. Percent Change From Baseline in Percentage of Patients Continent

    Due to lack of evaluable data, analysis for this outcome measure was not performed.

    Time frame: Baseline (Week 2), Week 14

07

Results

Posted Jan 21, 2013
Limitations and caveats
Due to lack of evaluable data, analysis for the secondary outcome measures was not performed.

Participant flow

Participant flow — Overall Study
MilestoneTrospium Chloride XR 60 mgPlacebo
Started6463
Completed5959
Not completed54

Outcome measures

PrimaryPercent Change From Baseline in Urinary Urgency Incontinence (UUI)

Patients recorded information about UUI (accidental leakage, urgency associated with void and urgency severity) in a 3-day diary at Baseline (Week 2) and Week 14. The daily average episodes of UUI was the sum of all UUI episodes over valid diary days during the 3-day diary period divided by the valid number of diary days with at least one valid bladder entry. The percent change from baseline was calculated as (Mean UUI at Week 14- Mean UUI at Week 2)/ Mean UUI at Week 2 X 100. A negative number percent change from baseline indicated an improvement.

Time frame:
Baseline (Week 2), Week 14
Reported as:
Mean · Percent change
Percent Change From Baseline in Urinary Urgency Incontinence (UUI)
Percent changeTrospium Chloride XR 60 mgPlacebo
Percent Change From Baseline in Urinary Urgency Incontinence (UUI)-23.7 ± 36.1657.8 ± 275.3
SecondaryPercent Change From Baseline in Urgency Severity Associated With Toilet Voids

Due to lack of evaluable data, analysis for this outcome measure was not performed.

Time frame:
Baseline (Week 2), Week 14

No measurements were reported for this outcome.

SecondaryPercent Change From Baseline in Voided Volume

Due to lack of evaluable data, analysis for this outcome measure was not performed.

Time frame:
Baseline (Week 2), Week 14

No measurements were reported for this outcome.

SecondaryPercent Change From Baseline in Over Active Bladder (OAB)-Symptom Composite Score

Due to lack of evaluable data, analysis for this outcome measure was not performed.

Time frame:
Baseline (Week 2), Week 14

No measurements were reported for this outcome.

SecondaryPercent Change From Baseline in Percentage of Patients Continent

Due to lack of evaluable data, analysis for this outcome measure was not performed.

Time frame:
Baseline (Week 2), Week 14

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trospium Chloride XR 60 mg—0/64 (0%)6/64 (9.4%)
Placebo—1/63 (1.6%)3/63 (4.8%)
Most frequent serious events
Most frequent serious events
EventTrospium Chloride XR 60 mgPlacebo
Atrial fibrillationCardiac disorders0/641/63
Most frequent other events
Most frequent other events
EventTrospium Chloride XR 60 mgPlacebo
Dry mouthGeneral disorders6/643/63

Baseline characteristics

Age, Customized
Age, Customized(Participants)Trospium Chloride XR 60 mgPlaceboTotal
<18 years000
18 to 75 years6463127
>75 years000
Sex: Female, Male
Sex: Female, Male(Participants)Trospium Chloride XR 60 mgPlaceboTotal
Female6463127
Male000
08

Study locations

1 site
  • La Mesa, California, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2009, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2013, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2009
First posted
Jul 2, 2009
Start
Jul 2009
Primary completionActual
Dec 2011
CompletionActual
Dec 2011
Results first posted
Jan 21, 2013
Last update
Jan 21, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00932022
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Jul 2, 2009
Start date
Jul 2009
Primary completion
Dec 2011
Completion
Dec 2011
Results posted
Jan 21, 2013
Last update
Jan 21, 2013

Study contacts

Medical Director
study director · Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trospium chloride

Start the discussion